Literature DB >> 22496227

Cdk1 inhibition induces mutually inhibitory apoptosis and reactivation of Kaposi's sarcoma-associated herpesvirus.

Xudong Li1, Shijia Chen, Ren Sun.   

Abstract

Primary effusion lymphoma (PEL) cells are predominantly infected by the latent form of Kaposi's sarcoma-associated herpesvirus (KSHV), with virus reactivation occurring in a small percentage of cells. Latency enables KSHV to persist in the host cell and promotes tumorigenesis through viral gene expression, thus presenting a major barrier to the elimination of KSHV and the treatment of PEL. Therefore, it is important to identify cellular genes that are essential for PEL cell survival or the maintenance of KSHV latency. Here we report that cyclin-dependent kinase 1 (Cdk1) inhibition can induce both apoptosis and KSHV reactivation in a population of PEL cells. Caspases, but not p53, are required for PEL cell apoptosis induced by Cdk1 inhibition. p38 kinase is activated by Cdk1 inhibition and mediates KSHV reactivation. Interestingly, upon Cdk1 inhibition, KSHV is reactivated predominantly in the nonapoptotic subpopulation of PEL cells. We provide evidence that this is due to mutual inhibition between apoptosis and KSHV reactivation. In addition, we found that KSHV reactivation activates protein kinase B (AKT/PKB), which promotes cell survival and facilitates KSHV reactivation. Our study thus establishes a key role for Cdk1 in PEL cell survival and the maintenance of KSHV latency and reveals a multifaceted relationship between KSHV reactivation and PEL cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496227      PMCID: PMC3393555          DOI: 10.1128/JVI.06240-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen.

Authors:  L Rainbow; G M Platt; G R Simpson; R Sarid; S J Gao; H Stoiber; C S Herrington; P S Moore; T F Schulz
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus.

Authors:  D Dittmer; M Lagunoff; R Renne; K Staskus; A Haase; D Ganem
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Xudong Li; Shijia Chen; Jun Feng; Hongyu Deng; Ren Sun
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

4.  The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1.

Authors:  D Godden-Kent; S J Talbot; C Boshoff; Y Chang; P Moore; R A Weiss; S Mittnacht
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).

Authors:  R Sarid; O Flore; R A Bohenzky; Y Chang; P S Moore
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 6.  Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma.

Authors:  R F Ambinder; K D Robertson; S M Moore; J Yang
Journal:  Semin Cancer Biol       Date:  1996-08       Impact factor: 15.707

7.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sun; S F Lin; L Gradoville; Y Yuan; F Zhu; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein.

Authors:  D M Lukac; R Renne; J R Kirshner; D Ganem
Journal:  Virology       Date:  1998-12-20       Impact factor: 3.616

9.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

Authors:  N S Gray; L Wodicka; A M Thunnissen; T C Norman; S Kwon; F H Espinoza; D O Morgan; G Barnes; S LeClerc; L Meijer; S H Kim; D J Lockhart; P G Schultz
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728

10.  Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.

Authors:  K Inaba; S Turley; F Yamaide; T Iyoda; K Mahnke; M Inaba; M Pack; M Subklewe; B Sauter; D Sheff; M Albert; N Bhardwaj; I Mellman; R M Steinman
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  5 in total

1.  A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.

Authors:  Crystal Woodard; Gangling Liao; C Rory Goodwin; Jianfei Hu; Zhi Xie; Thaila F Dos Reis; Rob Newman; Heesool Rho; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

Review 2.  The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.

Authors:  XueQiao Liu; Jeffrey I Cohen
Journal:  Virology       Date:  2015-03-20       Impact factor: 3.616

3.  Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication.

Authors:  Giuseppe Balistreri; Johanna Viiliäinen; Mikko Turunen; Raquel Diaz; Lauri Lyly; Pirita Pekkonen; Juha Rantala; Krista Ojala; Grzegorz Sarek; Mari Teesalu; Oxana Denisova; Karita Peltonen; Ilkka Julkunen; Markku Varjosalo; Denis Kainov; Olli Kallioniemi; Marikki Laiho; Jussi Taipale; Sampsa Hautaniemi; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2016-02-18       Impact factor: 6.823

Review 4.  Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.

Authors:  Jeffrey I Cohen
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

5.  SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.

Authors:  Wayne W Yeh; Yin-Quan Chen; Wan-Shan Yang; Yung-Chih Hong; Sen Kao; Tze-Tze Liu; Ting-Wen Chen; Lung Chang; Pei-Ching Chang
Journal:  J Virol       Date:  2022-08-01       Impact factor: 6.549

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.